Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Auro Labs.
Quarter-by-quarter operating performance
| Sep 2024 | Jun 2025 | Sep 2025 | |
|---|---|---|---|
| Sales + | 3.10 | 2.77 | 8.84 |
| Expenses + | 2.38 | 2.74 | 6.49 |
| Operating Profit | 0.72 | 0.03 | 2.35 |
| OPM % | 23.23% | 1.08% | 26.58% |
| Other Income + | 0.31 | 0.42 | 0.98 |
| Interest | 0.28 | 0.28 | 0.96 |
| Depreciation | 0.27 | 0.27 | 0.65 |
| Profit before tax | 0.48 | -0.10 | 1.72 |
| Tax % | 25.00% | 0.00% | 58.14% |
| Net Profit + | 0.36 | -0.11 | 0.72 |
| EPS in Rs | 0.58 | -0.18 | 1.16 |
Financials of Auro Labs.
Annual income statement trend
| Mar 2025 | |
|---|---|
| Sales + | 19.40 |
| Expenses + | 16.00 |
| Operating Profit | 3.40 |
| OPM % | 17.53% |
| Other Income + | 0.66 |
| Interest | 1.08 |
| Depreciation | 1.10 |
| Profit before tax | 1.88 |
| Tax % | 2.13% |
| Net Profit + | 1.84 |
| EPS in Rs | 2.95 |
| Dividend Payout % | 0.00% |
Financials of Auro Labs.
Capital structure and asset base
| Mar 2025 | Sep 2025 | |
|---|---|---|
| Equity Capital | 6.23 | 6.23 |
| Reserves | 36.74 | 37.35 |
| Borrowings + | 42.72 | 43.94 |
| Other Liabilities + | 13.41 | 23.25 |
| Total Liabilities | 99.10 | 110.77 |
| Fixed Assets + | 21.05 | 76.84 |
| CWIP | 56.48 | 10.37 |
| Investments | 0.05 | 0.05 |
| Other Assets + | 21.52 | 23.51 |
| Total Assets | 99.10 | 110.77 |
Financials of Auro Labs.
Operating, investing and financing cash movement
| Mar 2025 | |
|---|---|
| Cash from Operating Activity + | |
| Cash from Investing Activity + | |
| Cash from Financing Activity + | |
| Net Cash Flow | |
| Free Cash Flow | |
| CFO/OP |
Financials of Auro Labs.
Working capital efficiency and return ratios
| Mar 2025 | |
|---|---|
| Debtor Days | 176.67 |
| Inventory Days | 145.45 |
| Days Payable | 246.11 |
| Cash Conversion Cycle | 76.01 |
| Working Capital Days | -14.30 |
| ROCE % |
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…